Tyr99
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Tyr99 - YB-1 (human)

Site Information
AMBIGUOUS SITES: CSDA (human):
KKNNPRKyLRSVGDG   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: YB‑1 (rat): (Y97), YB‑1 (mouse): (Y97)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15416754

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (1, 2, 3, 4)
Disease tissue studied: gastric cancer (2), gastric carcinoma (2)
Relevant cell line - cell type - tissue: HeLa (cervical) (3), Jurkat (T lymphocyte) (4), MKN-45 (gastric) (2)




References

1

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

2

(2010) CST Curation Set: 9236; Year: 2010; Biosample/Treatment: cell line, MKN-45/pervanadate & calyculin; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

3

(2010) CST Curation Set: 9245; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

4

(2008) CST Curation Set: 4818; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.